Yutaka Hanazono
Overview
Explore the profile of Yutaka Hanazono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abe T, Endo K, Hanazono Y, Kobayashi E
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201296
Luminescent technology based on the luciferin-luciferase reaction has been extensively employed across various disciplines as a quantitative imaging modality. Owing to its non-invasive imaging capacity, it has evolved as a...
2.
Minegishi M, Kuchimaru T, Nishikawa K, Isagawa T, Iwano S, Iida K, et al.
Nat Commun
. 2023 Dec;
14(1):8031.
PMID: 38052804
Cancer cells inevitably interact with neighboring host tissue-resident cells during the process of metastatic colonization, establishing a metastatic niche to fuel their survival, growth, and invasion. However, the underlying mechanisms...
3.
PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
Hiramoto T, Kashiwakura Y, Hayakawa M, Baatartsogt N, Kamoshita N, Abe T, et al.
Commun Med (Lond)
. 2023 Apr;
3(1):56.
PMID: 37076593
Background: Base editing via CRISPR-Cas9 has garnered attention as a method for correcting disease-specific mutations without causing double-strand breaks, thereby avoiding large deletions and translocations in the host chromosome. However,...
4.
Hara H, Munkh-Erdene N, Byambaa S, Hanazono Y
Methods Mol Biol
. 2023 Feb;
2637:213-221.
PMID: 36773149
Knock-in therapy, in which an insertion site can be controlled, would be more suitable for the treatment of genetic blood disorders as compared to conventional gene therapy with lentivirus vectors...
5.
Anzai T, Hara H, Chanthra N, Sadahiro T, Ieda M, Hanazono Y, et al.
Methods Mol Biol
. 2021 Jul;
2320:247-259.
PMID: 34302663
A knock-in can generate fluorescent or Cre-reporter under the control of an endogenous promoter. It also generates knock-out or tagged-protein with fluorescent protein and short tags for tracking and purification....
6.
Ahmed R, Chanthra N, Anzai T, Koiwai K, Murakami T, Suzuki H, et al.
J Vis Exp
. 2021 Mar;
(169).
PMID: 33749676
Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) can be produced from both embryonic and induced pluripotent stem (ES/iPS) cells. These cells provide promising sources for cardiac disease modeling. For cardiomyopathies, sarcomere shortening...
7.
Byambaa S, Uosaki H, Ohmori T, Hara H, Endo H, Nureki O, et al.
Mol Ther Methods Clin Dev
. 2021 Feb;
20:451-462.
PMID: 33614821
We conducted two lines of genome-editing experiments of mouse hematopoietic stem cells (HSCs) with the clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated protein 9 (Cas9). First, to evaluate...
8.
Abe T, Uosaki H, Shibata H, Hara H, Sarentonglaga B, Nagao Y, et al.
Exp Hematol
. 2021 Jan;
95:46-57.e8.
PMID: 33395577
We report that a sheep fetal liver provides a microenvironment for generating hematopoietic cells with long-term engrafting capacity and multilineage differentiation potential from human induced pluripotent stem cell (iPSC)-derived hemogenic...
9.
Chanthra N, Abe T, Miyamoto M, Sekiguchi K, Kwon C, Hanazono Y, et al.
Sci Rep
. 2020 Mar;
10(1):4249.
PMID: 32144297
Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) hold great promise for disease modeling and drug discovery. However, PSC-CMs exhibit immature phenotypes in culture, and the lack of maturity limits their broad applications....
10.
Byambaa S, Uosaki H, Hara H, Nagao Y, Abe T, Shibata H, et al.
Exp Anim
. 2019 Dec;
69(2):189-198.
PMID: 31801915
X-linked severe combined immunodeficiency (X-SCID) is an inherited genetic disorder. A majority of X-SCID subjects carries point mutations in the Interleukin-2 receptor gamma chain (IL2RG) gene. In contrast, Il2rg-knockout mice...